 Home > Biochemistry News > Biotechnology News > Sanofi/Regeneron Libtayo+ chemotherapy phase 3 clinical efficacy significantly prolongs overall survival

Sanofi/Regeneron Libtayo+ chemotherapy phase 3 clinical efficacy significantly prolongs overall survival

 Last Update: 2021-11-05
 Source: Internet
 Author: User

Tags

1 2 5 6

tucker safety products

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Sanofi and its partner Regeneron recently announced the evaluation of anti-PD-1 therapy Libtayo (cemiplimab) combined with platinum-containing dual-action chemotherapy for the treatment of stage 3 EMPOWER-Lung 3 in patients with advanced non-small cell lung cancer (NSCLC) The positive result of the test

The trial enrolled patients with locally advanced or metastatic disease, tumors with squamous or non-squamous histology, and all PD-L1 expression levels, and compared Libtayo+ chemotherapy with chemotherapy alone

——Overall survival (OS): Compared with the chemotherapy group, the Libtayo+ chemotherapy group has significantly longer OS (median OS: 22 months vs 13 months) and a 29% reduction in the risk of death (HR=0.

——Progress-free survival (PFS): Compared with the chemotherapy group, the PFS of the Libtayo+ chemotherapy group was significantly prolonged (median PFS: 8 months vs.

——Remission: The objective response rate (ORR) in the Libtayo+ chemotherapy group was 43%, and the median duration of response (DOR) was 16 months; the ORR in the chemotherapy group was 23% and the median DOR was 7 months

-Patient-reported results: Good results reported by patients were observed in this trial

——Safety: No new Libtayo safety signal was found in this test

The data from the Phase 3 EMPOWER-Lung 3 trial will serve as the basis for the submission of regulatory application documents in the United States and the European Union

Lung cancer is the leading cause of cancer deaths worldwide

Libtayo is an anti-PD-(L)1 inhibitor, which aims to use the body's own immune system to fight cancer, block the PD-1/PD-L1 signaling pathway to kill cancer cells, and has the potential to treat many types of tumors

Libtayo uses Regeneron’s patented Velocimmune technology platform to create and optimize it.

Note: The original text has been deleted

Original source: Libtayo (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.